骨髓瘤的骨髓移植
Marrow transplantation for myeloma.
作者信息
Fermand J P, Brouet J C
机构信息
Department of Hematology and Immunopathology, Hôpital Saint-Louis, Paris, France.
出版信息
Annu Rev Med. 1995;46:299-307. doi: 10.1146/annurev.med.46.1.299.
High-dose therapy with hemopoietic stem cell support in multiple myeloma (MM) has been used for 10 years. This approach is currently the most promising form of treatment for this disease. We review here its rationale and the results of clinical trials according to the source of hematopoietic stem cells [allogeneic or autologous, bone marrow or blood]. Finally, we discuss the ongoing uncertainties regarding the utility of this treatment and the future prospects for high-dose therapy in MM.
多发性骨髓瘤（MM）的造血干细胞支持下的高剂量治疗已应用了10年。目前，这种方法是该疾病最有前景的治疗形式。我们在此根据造血干细胞的来源[异基因或自体、骨髓或血液]回顾其理论依据和临床试验结果。最后，我们讨论关于这种治疗效用的持续不确定性以及MM高剂量治疗的未来前景。
Zotero 插件